Semaglutide and Metabolism: Mechanism and Adaptation

Does semaglutide speed up metabolism?

Semaglutide primarily reduces calorie intake through GLP-1 receptors involved in appetite and also delays gastric emptying. The weight-loss trials cited here measured body weight and do not show that it raises metabolic rate [4][5].

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1 [1]. It binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake, and it delays gastric emptying [1].

The size of the effect is large. In STEP 1, 1,961 adults with obesity, or overweight plus a weight-related condition, and without diabetes lost a mean 14.9% of body weight over 68 weeks on 2.4 mg weekly, versus 2.4% on placebo, a difference of 12.4 percentage points [4]. Higher doses produce more: in STEP UP, 1,407 adults without diabetes lost 18.7% on 7.2 mg, 15.6% on 2.4 mg and 3.9% on placebo at 72 weeks [5].

Weight loss is smaller in people with type 2 diabetes. In STEP 2, 1,210 adults with diabetes lost 9.6% on 2.4 mg versus 3.4% on placebo at 68 weeks [6].

How is semaglutide itself metabolized?

Injected semaglutide is 89% bioavailable, peaks 1 to 3 days after a dose, and is more than 99% bound to albumin. Its elimination half-life is about 1 week [1]. After the last 2.4 mg or 7.2 mg injection, or the last 25 mg tablet, the drug stays in the body for about 5 to 7 weeks [1].

It is not processed by the cytochrome P450 enzymes that handle most small-molecule drugs. Semaglutide is broken down by proteolytic cleavage of its peptide backbone and beta-oxidation of its fatty acid side chain, and about 3% of a dose is excreted unchanged in urine [1]. Steady-state concentrations are about 75 nmol/L on 2.4 mg weekly and about 230 nmol/L on 7.2 mg weekly [1].

The tablets are a different pharmacokinetic proposition. They are co-formulated with SNAC to help absorption, mainly in the stomach; oral bioavailability is about 1% to 2% against 89% for the injection, with a peak about 1 hour after the dose, and tablet and injection milligrams are not interchangeable [1].

Does kidney or liver function change the dose?

The Ozempic label recommends no dose adjustment for renal or hepatic impairment [7]. Wegovy pharmacokinetic studies found no clinically significant differences in semaglutide exposure across eGFR 30 to under 90 or Child-Pugh A to C hepatic impairment [1].

Vomiting or diarrhea can cause fluid loss. The Wegovy label warns about acute kidney injury due to volume depletion, particularly during dose escalation and in people with existing kidney impairment [1]. It reports acute kidney injury in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults) [1].

What happens to weight after stopping?

The STEP 1 extension followed 327 participants after treatment ended. Mean weight loss at week 68 had been 17.3% on semaglutide versus 2.0% on placebo; by week 120, a year off treatment, the semaglutide group had regained 11.6 percentage points, for a net loss of 5.6% versus 0.1% on placebo, and most cardiometabolic improvements had moved back toward baseline [2].

STEP 4 tested continuing semaglutide versus switching to placebo. After a 20-week run-in in which 803 adults lost a mean 10.6% of body weight, they were randomized to continue 2.4 mg weekly or switch to placebo for 48 weeks. From week 20 to week 68, weight changed by -7.9% on continued semaglutide and +6.9% on placebo, a difference of 14.8 percentage points [3].

Does semaglutide change how other medicines are metabolized?

Semaglutide delays gastric emptying, so it can change how quickly oral drugs are absorbed. The label says to consider closer monitoring for oral drugs with a narrow therapeutic index [1]. With the tablets, levothyroxine total exposure rose 33% [1].

A drug-interaction study found no clinically significant effect on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin, and omeprazole did not change semaglutide levels [1]. Semaglutide has very low potential to inhibit or induce CYP enzymes [1]. The semaglutide labels carry no advice to switch or back up oral contraceptives [1].

What does the label say to watch for?

The most common reactions are gastrointestinal. In the pooled Wegovy 2.4 mg trials (2,116 on semaglutide, 1,261 on placebo), nausea occurred in 44% versus 16%, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, constipation in 24% versus 11%, and any GI reaction in 73% versus 47%; 6.8% versus 3.2% stopped treatment because of an adverse reaction (most often nausea, vomiting or diarrhea), and severe GI reactions occurred in 4.1% versus 0.9% [1].

Gallbladder disease is also listed: cholelithiasis occurred in 1.6% versus 0.7% and cholecystitis in 0.6% versus 0.2% in the adult injection trials [1].

Separately, the Wegovy label reports a mean heart rate increase of 1 to 4 beats per minute, with a rise of 20 beats per minute or more in 26% versus 16% [1]. Hair loss was reported in 3% versus 1% [1].

Which products do these numbers come from?

The adverse-reaction percentages above are from trials of Wegovy 2.4 mg injection [1]. Bioavailability is 89% for the subcutaneous injection and about 1% to 2% for Wegovy tablets [1]. Wegovy carries the weight-management indication; Ozempic and Rybelsus are indicated for type 2 diabetes [7][8][1].

Compounded semaglutide is not FDA approved and is not reviewed for safety, effectiveness or quality before marketing [9]. HealthRX.com offers compounded semaglutide by prescription.